These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 2972301)
41. Antistaphylococcal activity of teicoplanin in association with other antibiotics. Cruciani M; Concia E; Monzillo V; Marone P; Perversi L Microbiologica; 1987 Apr; 10(2):197-207. PubMed ID: 2953955 [TBL] [Abstract][Full Text] [Related]
42. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy. Asseray N; Jacqueline C; Le Mabecque V; Batard E; Bugnon D; Potel G; Caillon J Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789 [TBL] [Abstract][Full Text] [Related]
43. Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus. Maple PA; Hamilton-Miller JM; Brumfitt W J Antimicrob Chemother; 1989 Apr; 23(4):517-25. PubMed ID: 2526111 [TBL] [Abstract][Full Text] [Related]
44. [Recent trend and development of novel antimicrobial agents for MRSA infections]. Nishino T Nihon Rinsho; 1992 May; 50(5):1066-74. PubMed ID: 1324332 [TBL] [Abstract][Full Text] [Related]
45. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Saginur R; Stdenis M; Ferris W; Aaron SD; Chan F; Lee C; Ramotar K Antimicrob Agents Chemother; 2006 Jan; 50(1):55-61. PubMed ID: 16377667 [TBL] [Abstract][Full Text] [Related]
46. In vitro activity of teicoplanin compared with vancomycin against methicillin-resistant Staphylococcus aureus derived from cystic fibrosis sputum. Arrieta AC; Stutman HR; Akaniro JC; Vargas OM Diagn Microbiol Infect Dis; 1992; 15(3):247-51. PubMed ID: 1533825 [TBL] [Abstract][Full Text] [Related]
47. In-vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin. Cooper MA; Jin YF; Ashby JP; Andrews JM; Wise R J Antimicrob Chemother; 1990 Aug; 26(2):203-7. PubMed ID: 2145256 [TBL] [Abstract][Full Text] [Related]
48. Effect of vancomycin and teicoplanin alone or in combination with fusidic acid or amikacin against methicillin-resistant staphylococci. Roussel-Delvallez M; Wallet F; Barbiery P; Courcol RJ J Chemother; 1997 Feb; 9(1):5-8. PubMed ID: 9106011 [TBL] [Abstract][Full Text] [Related]
49. Teicoplanin and rifampicin singly and in combination in the treatment of experimental Staphylococcus epidermidis endocarditis in the rabbit model. Tuazon CU; Washburn D J Antimicrob Chemother; 1987 Aug; 20(2):233-7. PubMed ID: 2959643 [TBL] [Abstract][Full Text] [Related]
50. Cephalosporins, vancomycin, aminoglycosides and other drugs, especially in combination, for the treatment of methicillin-resistant staphylococcal infections. Klastersky J; Van der Auwera P J Antimicrob Chemother; 1986 Mar; 17 Suppl A():19-24. PubMed ID: 2940212 [TBL] [Abstract][Full Text] [Related]
51. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin. Pohlod DJ; Saravolatz LD; Somerville MM J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646 [TBL] [Abstract][Full Text] [Related]
52. In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections. Garcia R; Raad I Eur J Clin Microbiol Infect Dis; 1996 Dec; 15(12):933-6. PubMed ID: 9031876 [TBL] [Abstract][Full Text] [Related]
53. In vitro activity of vancomycin and teicoplanin against anaerobic bacteria. Robbins MJ; Marais R; Felmingham D; Ridgway GL; Grüneberg RN Drugs Exp Clin Res; 1987; 13(9):551-4. PubMed ID: 2962846 [TBL] [Abstract][Full Text] [Related]
54. Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin. Lagast H; Dodion P; Klastersky J J Antimicrob Chemother; 1986 Oct; 18(4):513-20. PubMed ID: 2945811 [TBL] [Abstract][Full Text] [Related]
55. Evaluation of in vitro activity of teicoplanin against recent clinical isolates. Nani E; Amato G; Anzivino D; Covelli B; Lembo M Chemioterapia; 1988 Feb; 7(1):20-3. PubMed ID: 2967737 [TBL] [Abstract][Full Text] [Related]
56. In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus. Foldes M; Munro R; Sorrell TC; Shanker S; Toohey M J Antimicrob Chemother; 1983 Jan; 11(1):21-6. PubMed ID: 6826485 [TBL] [Abstract][Full Text] [Related]
57. Technical factors influencing the bactericidal activity of teicoplanin against staphylococci. Pasticci MB; Moretti A; Frongillo RF; Baldelli F; Moretti MV; Pauluzzi S Boll Ist Sieroter Milan; 1989; 68(2):101-7. PubMed ID: 2535247 [TBL] [Abstract][Full Text] [Related]
58. [In vitro kinetics of the activity of fusidic acid and fluoroquinolones combinations against staphylococci according to methicillin-resistance phenotype. Implications for the treatment of osteoarticular infections]. Reynaud AE; Espaze EP; Coste-Burel M; Richet H Pathol Biol (Paris); 1992 May; 40(5):466-70. PubMed ID: 1495828 [TBL] [Abstract][Full Text] [Related]
59. In-vitro synergy testing of triple antibiotic combinations against Staphylococcus epidermidis isolates from patients with endocarditis. Yu VL; Zuravleff JJ; Bornholm J; Archer G J Antimicrob Chemother; 1984 Oct; 14(4):359-66. PubMed ID: 6501129 [TBL] [Abstract][Full Text] [Related]
60. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. Pistella E; Falcone M; Baiocchi P; Pompeo ME; Pierciaccante A; Penni A; Venditti M Infez Med; 2005 Jun; 13(2):97-102. PubMed ID: 16220029 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]